Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613613 · ClinicalTrials.gov registry record
Fenofibrate and Pharmacogenetic Impact in Dyslipidemia
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 56
- Enrollment target
NCT00613613 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 56 participants.
The verdict
NCT00613613 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
The purpose of the study is to learn whether genetics plays a role in predicting response to a commonly used and FDA (Food and Drug Administration) approved medication for lowering triglycerides and cholesterol. The hypothesis: The pharmacogenetics of genes which affect drug metabolism (how the body handles the drug) and drug targets (how the drug acts on the body) influences how a person responds to the lipid lowering medication-fenofibrate.
Interventions
- DRUG fenofibrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00613613
The ClinicalTrials.gov registry entry for NCT00613613 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fenofibrate is the first listed.
NCT00613613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00613613 about?
NCT00613613 is a clinical study titled "Fenofibrate and Pharmacogenetic Impact in Dyslipidemia". The purpose of the study is to learn whether genetics plays a role in predicting response to a commonly used and FDA (Food and Drug Administration) approved medication for lowering triglycerides and cholesterol. The hypothesis: The pharmacogenetics of genes which affect drug metabolism (how the body...
What is the current status of trial NCT00613613?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2008-01. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00613613?
The interventions under investigation include: fenofibrate (DRUG).
Who is sponsoring clinical trial NCT00613613?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.